Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STOP-VD: Discontinuation of Vasoactive Drugs in Reflex Syncope
NCT02137278Phase 3Completed
- Sponsor
- GIMSI
- Start
- Mar 2014
- Primary completion
- Dec 2015
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial (2 arms), sponsored by GIMSI. Primary endpoint: Recurrence of syncope or presyncope and adverse events at 2 years. Started Mar 2014; status: completed.
Beyond the preview
Go deeper on NCT02137278.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02137278.